Abstract:Over the last decade, more than 300 phase I and phase II gene-based clinical trials have been conducted worldwide for the treatment of cancer and monogenic disorders. Lately, these trials have been extended to the treatment of AIDS and, to a lesser extent, cardiovascular diseases. There are 27 currently active gene therapy protocols for the treatment of HIV-1 infection in the USA. Preclinical studies are currently in progress to evaluate the possibility of increasing the number of gene therapy clinical trials for cardiopathies, and of beginning new gene therapy programs for neurologic illnesses, autoimmuno diseases, allergies, regeneration of tissues, and to implement procedures of allogeneic tissues or cell transplantation. In addition, gene transfer technology has allowed for the development of innovative vaccine design, known as genetic immunization. This technique has already been applied in the AIDS vaccine programs in the USA. These programs aim to confer protective immunity against HIV-1 transmission to individuals who are at risk of infection. Research programs have also been considered to develop therapeutic vaccines for patients with AIDS and generate either preventive or therapeutic vaccines against malaria, tuberculosis, hepatitis A, B and C viruses, influenza virus, La Crosse virus, and Ebola virus. The potential therapeutic applications of gene transfer technology are enormous. However, the effectiveness of gene therapy programs is still questioned. Furthermore, there is growing concern over the matter of safety of gene delivery and controversy has arisen over the proposal to begin in utero gene therapy clinical trials for the treatment of inherited genetic disorders. From this standpoint, despite the latest significant achievements reported in vector design, it is not possible to predict to what extent gene therapeutic interventions will be effective in patients, and in what time frame.

Progress and prospects: gene therapy for genetic diseases with helper-dependent adenoviral vectors

Gene therapy with helper-dependent adenoviral vectors: lessons from studies in large animal models

[Advances in Helper-Dependent Adenoviral Vector--a Review Review].

Adeno‐associated Virus Vectors for Gene Therapy—focusing on Melanoma

The evolution of adenoviral vectors through genetic and chemical surface modifications

Advances of Recombinant Adenoviral Vectors in Preclinical and Clinical Applications

Towards Clinical Implementation of Adeno-Associated Virus (AAV) Vectors for Cancer Gene Therapy: Current Status and Future Perspectives

Adeno-associated virus vector as a platform for gene therapy delivery

Engineering adeno-associated virus vectors for gene therapy

Immune Responses to Viral Gene Therapy Vectors

Intracellular trafficking of adeno-associated virus (AAV) vectors: challenges and future directions

Latest Developments in Gene Transfer Technology: Achievements, Perspectives, and Controversies over Therapeutic Applications

Adenoviral Vectors for Gene Therapy of Hereditary Diseases

A primer to gene therapy: Progress, prospects, and problems

Adenoviral gene therapy for cancer: from vectors to targeted and replication competent agents (review).

Adeno-associated viral vectors for correction of inborn errors of metabolism: progressing towards clinical application.

Next-generation strategies to improve safety and efficacy of adeno-associated virus-based gene therapy for hemophilia: lessons from clinical trials in other gene therapies

Clinical development on the frontier: gene therapy for duchenne muscular dystrophy

Changing trends in the development of AAV-based gene therapies: a meta-analysis of past and present therapies

Viral vector platforms within the gene therapy landscape

Gene Therapy Progress and Prospects: Nonviral vectors